Intra-Cellular Therapies, Inc. which can be found using ticker (ITCI) now have 12 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 98 and 58 calculating the average target price we see $76.50. Now with the previous closing price of $62.98 this is indicating there is a potential upside of 21.5%. It’s also worth noting that there is a 50 day moving average of $56.98 and the 200 moving average now moves to $51.60. The market cap for the company is 6.07B. The stock price for the company is currently 63.27 USD
The potential market cap would be $7,372,098,593 based on the market consensus.
USD
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 3.28 and a -18.81% return on assets.
